Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis.
Inflammatory bowel disease
Inflammatory bowel disease-related arthritis
Psoriatic arthritis
Spondyloarthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
17
01
2022
accepted:
14
03
2022
pubmed:
10
5
2022
medline:
9
9
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
The purpose of this study was to clarify the clinical characteristics of spondyloarthritis (SpA) patients with inflammatory bowel disease (IBD) compared to those without IBD. Furthermore, among patients with SpA and IBD, we aimed to clarify what clinical characteristics lead rheumatologists to diagnose "IBD-related arthritis." Utilizing SpA and psoriatic arthritis (PsA) patients' data from an international, cross-sectional, observational study, we analyzed information on demographics and disease characteristics, dichotomizing patients by IBD status. The presence or absence of IBD was determined based on data collection of treating rheumatologists. Patients with SpA (including PsA) and IBD were also categorized based on treating rheumatologists' definitive diagnosis in regard to SpA type, and compared by whether the patients had IBD-related arthritis or not. Among 4465 SpA patients, 287 (6.4%, 95%CI 5.7-7.2%) were identified with IBD. Compared to SpA patients without IBD, patients with SpA and IBD had a longer diagnostic delay (5.1 vs. 2.9 years, p < 0.001). In patients with SpA and IBD, 111 (38.7%, 95%CI 33.0-44.6%) were diagnosed with IBD-related arthritis. Multivariable analyses showed that HLA-B27 positivity [OR = 0.35, (95%CI 0.15-0.80)], psoriasis [OR = 0.14, (95%CI 0.04-0.50)], IBD as first symptom of SpA [OR = 3.32, (95%CI 1.84-6.01)], and need for IBD-specific treatment [OR = 5.41, (95%CI 2.02-14.50)] were independently associated with the definitive diagnosis of IBD-related arthritis. Collaboration with gastroenterologists is needed to shorten the diagnostic delay in patients with SpA and IBD. The recognition of the factors for the diagnosis of "IBD-related arthritis" may lead to the elucidation of the pathogenesis.
Identifiants
pubmed: 35532790
doi: 10.1007/s00296-022-05117-0
pii: 10.1007/s00296-022-05117-0
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1751-1766Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gracey E, Vereecke L, McGovern D et al (2020) Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 16:415–433. https://doi.org/10.1038/s41584-020-0454-9
doi: 10.1038/s41584-020-0454-9
pubmed: 32661321
Moltó A, Etcheto A, van der Heijde D et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75:1016–1023. https://doi.org/10.1136/annrheumdis-2015-208174
doi: 10.1136/annrheumdis-2015-208174
pubmed: 26489703
Ng SC, Shi HY, Hamidi N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0
doi: 10.1016/S0140-6736(17)32448-0
pubmed: 29050646
Van Praet L, Van den Bosch FE, Jacques P et al (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417. https://doi.org/10.1136/annrheumdis-2012-202135
doi: 10.1136/annrheumdis-2012-202135
pubmed: 23139267
Atzeni F, Defendenti C, Ditto MC et al (2014) Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 13:20–23. https://doi.org/10.1016/j.autrev.2013.06.006
doi: 10.1016/j.autrev.2013.06.006
pubmed: 23774109
Hiller A, Biedermann L, Fournier N et al (2019) The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS One 14:e0211554. https://doi.org/10.1371/journal.pone.0211554
doi: 10.1371/journal.pone.0211554
pubmed: 31039159
pmcid: 6490952
Karreman MC, Luime JJ, Hazes JMW, Weel AEAM (2017) The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:631–642. https://doi.org/10.1093/ecco-jcc/jjw199
doi: 10.1093/ecco-jcc/jjw199
pubmed: 28453761
Van Praet L, Jans L, Carron P et al (2014) Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 73:1186–1189. https://doi.org/10.1136/annrheumdis-2013-203854
doi: 10.1136/annrheumdis-2013-203854
pubmed: 24276368
Essers I, Ramiro S, Stolwijk C et al (2015) Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford) 54:633–640. https://doi.org/10.1093/rheumatology/keu388
doi: 10.1093/rheumatology/keu388
Benavent D, Plasencia C, Poddubnyy D et al (2021) Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. Semin Arthritis Rheum 51:766–774. https://doi.org/10.1016/j.semarthrit.2021.04.018
doi: 10.1016/j.semarthrit.2021.04.018
pubmed: 34144387
Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD (2021) Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum 51:880–887. https://doi.org/10.1016/j.semarthrit.2021.06.006
doi: 10.1016/j.semarthrit.2021.06.006
pubmed: 34198146
López-Medina C, Molto A, Sieper J et al (2021) Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 7:e001450. https://doi.org/10.1136/rmdopen-2020-001450
doi: 10.1136/rmdopen-2020-001450
pubmed: 33462157
pmcid: 7816910
Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783. https://doi.org/10.1136/ard.2009.108233
doi: 10.1136/ard.2009.108233
pubmed: 19297344
Rudwaleit M, van der Heijde D, Landewé R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31. https://doi.org/10.1136/ard.2010.133645
doi: 10.1136/ard.2010.133645
pubmed: 21109520
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673. https://doi.org/10.1002/art.21972
doi: 10.1002/art.21972
pubmed: 16871531
Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. https://doi.org/10.1136/ard.2008.094870
doi: 10.1136/ard.2008.094870
pubmed: 18625618
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291
pubmed: 7699630
Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285
pubmed: 7699629
Kiltz U, van der Heijde D, Boonen A et al (2018) Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 77:1311–1317. https://doi.org/10.1136/annrheumdis-2017-212076
doi: 10.1136/annrheumdis-2017-212076
pubmed: 29858176
Kazuki Y, Alexander B, Jonathan JC, et al (2021) Package ‘tableone’. Available from: https://cran.r-project.org/web/packages/tableone/ . Accessed 25 July 2021
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Shah SC, Khalili H, Gower-Rousseau C et al (2018) Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. Gastroenterology 155:1079–1089. https://doi.org/10.1053/j.gastro.2018.06.043
doi: 10.1053/j.gastro.2018.06.043
pubmed: 29958857
Benfaremo D, Luchetti MM, Di Carlo M et al (2021) Multicenter validation of the DETAIL Questionnaire for the screening of spondyloarthritis in patients with inflammatory bowel diseases. J Rheumatol 48:179–187. https://doi.org/10.3899/jrheum.200364
doi: 10.3899/jrheum.200364
pubmed: 32669448
Arévalo M, Gratacós Masmitjà J, Moreno M et al (2018) Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Res Ther 20:221. https://doi.org/10.1186/s13075-018-1724-7
doi: 10.1186/s13075-018-1724-7
pubmed: 30285828
pmcid: 6235234
Derakhshan MH, Dean L, Jones GT, Siebert S, Gaffney K (2020) Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. RMD Open 6:e001206. https://doi.org/10.1136/rmdopen-2020-001206
doi: 10.1136/rmdopen-2020-001206
pubmed: 32641447
pmcid: 7425116
Varkas G, Vastesaeger N, Cypers H et al (2018) Association of inflammatory bowel disease and acute anterior uveitis, but not psoriasis, with disease duration in patients with axial spondyloarthritis: results from two Belgian Nationwide Axial Spondyloarthritis Cohorts. Arthritis Rheumatol 70:1588–1596. https://doi.org/10.1002/art.40551
doi: 10.1002/art.40551
pubmed: 29740978
Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387–391. https://doi.org/10.1136/gut.42.3.387
doi: 10.1136/gut.42.3.387
pubmed: 9577346
pmcid: 1727027
Picchianti-Diamanti A, Lorenzetti R, Chimenti MS et al (2020) Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmun Rev 19:102457. https://doi.org/10.1016/j.autrev.2019.102457
doi: 10.1016/j.autrev.2019.102457
pubmed: 31838160
Cantini F, Niccoli L, Nannini C et al (2017) Case-control study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol 44:1341–1346. https://doi.org/10.3899/jrheum.161518
doi: 10.3899/jrheum.161518
pubmed: 28412702
Li WQ, Han JL, Chan AT, Qureshi AA (2013) Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis 72:1200–1205. https://doi.org/10.1136/annrheumdis-2012-202143
doi: 10.1136/annrheumdis-2012-202143
pubmed: 22941766
Takeuchi K, Smale S, Premchand P et al (2006) Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4:196–202. https://doi.org/10.1016/s1542-3565(05)00980-8
doi: 10.1016/s1542-3565(05)00980-8
pubmed: 16469680
Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS (2016) Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. J Clin Gastroenterol 50:152–156. https://doi.org/10.1097/MCG.0000000000000421
doi: 10.1097/MCG.0000000000000421
pubmed: 26485106
pmcid: 4703528
Olivieri I, Cantini F, Castiglione F et al (2014) Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 13:822–830. https://doi.org/10.1016/j.autrev.2014.04.003
doi: 10.1016/j.autrev.2014.04.003
pubmed: 24726868
McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG (2014) Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2014:CD003459. https://doi.org/10.1002/14651858.CD003459.pub4
doi: 10.1002/14651858.CD003459.pub4
pmcid: 7154581
Chande N, MacDonald JK, McDonald JW (2014) Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014:CD006618. https://doi.org/10.1002/14651858.CD006618.pub3
doi: 10.1002/14651858.CD006618.pub3
pmcid: 6486224
Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–1700. https://doi.org/10.1136/gutjnl-2011-301668
doi: 10.1136/gutjnl-2011-301668
pubmed: 22595313
Targan SR, Feagan B, Vermeire S et al (2016) A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol 111:1599–1607. https://doi.org/10.1038/ajg.2016.298
doi: 10.1038/ajg.2016.298
pubmed: 27481309
Penso L, Bergqvist C, Meyer A et al (2021) Risk of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis initiating interleukin 17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis Rheumatol. https://doi.org/10.1002/art.41923
doi: 10.1002/art.41923
Kavadichanda CG, Geng J, Bulusu SN, Negi VS, Raghavan M (2021) Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B(*)27 Connection. Front Immunol 12:601518. https://doi.org/10.3389/fimmu.2021.601518
doi: 10.3389/fimmu.2021.601518
pubmed: 33763060
pmcid: 7982681
de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M (2000) Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 27:2860–2865
pubmed: 11128677
Orchard TR, Holt H, Bradbury L et al (2009) The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn’s disease. Aliment Pharmacol Ther 29:193–197. https://doi.org/10.1111/j.1365-2036.2008.03868.x
doi: 10.1111/j.1365-2036.2008.03868.x
pubmed: 18945256
Kishimoto M, Yoshida K, Ichikawa N et al (2019) Clinical characteristics of patients with spondyloarthritis in Japan in comparison with other regions of the world. J Rheumatol 46:896–903. https://doi.org/10.3899/jrheum.180412
doi: 10.3899/jrheum.180412
pubmed: 30770497
Kishimoto M, Ono K, Fukui S et al (2021) Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open 7:e001752. https://doi.org/10.1136/rmdopen-2021-001752
doi: 10.1136/rmdopen-2021-001752
pubmed: 34531305
pmcid: 8449957